Online inquiry

IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ134MR)

This product GTTS-WQ134MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CA9 gene. The antibody can be applied in Kidney tumours research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001216.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 768
UniProt ID Q16790
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ134MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3721MR IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BAY 94-9343
GTTS-WQ8645MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ11710MR IVTScrip™ mRNA-Anti-IL13, MILR1444A(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MILR1444A
GTTS-WQ8129MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HH1
GTTS-WQ15832MR IVTScrip™ mRNA-Anti-CD3E&SSTR2, XmAb-18087(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA XmAb-18087
GTTS-WQ3609MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ858MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-176
GTTS-WQ14427MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RO 24-7375
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW